AeroLeads people directory · profile
Dena Grayson, Md, Phd Email & Phone Number
Senior Vice President, Clinical Development and Medical Affairs
at
Kyverna Therapeutics
1 work email found
@kerostx.com
LinkedIn matched
✓ Verified Jun 2026
4 data sources
Profile completeness 100%
Current company
Role
Senior Vice President, Clinical Development and Medical Affairs
Location
United States, United States, United States
Who is Dena Grayson, Md, Phd? Overview
A concise factual answer block for searchers comparing this professional profile.
Quick answer
Dena Grayson, Md, Phd is listed as Senior Vice President, Clinical Development and Medical Affairs at Kyverna Therapeutics, based in United States, United States, United States. AeroLeads shows a work email signal at kerostx.com and a matched LinkedIn profile for Dena Grayson, Md, Phd.
Dena Grayson, Md, Phd previously worked as Senior Vice President at Keros Therapeutics and Clinical Development and Medical Affairs Physician-Scientist at Biocryst Pharmaceuticals, Inc.. Dena Grayson, Md, Phd holds M.D., Ph.D., Medicine, Biochemistry from Washington University School Of Medicine In St. Louis.
Company email context
Email format at Kyverna Therapeutics
This section adds company-level context without repeating Dena Grayson, Md, Phd's masked contact details.
*@kerostx.com
68% confidence
AeroLeads found 1 current-domain work email signal for Dena Grayson, Md, Phd. Compare company email patterns before reaching out.
Profile bio
About Dena Grayson, Md, Phd
Dena Grayson, MD, PhD (née Dena Minning) is a physician-scientist with strong leadership skills, clear strategic vision, proven drug development and medical affairs expertise, and an outstanding ability to work cross-functionally and deliver under tight timelines. She led the successful early clinical development of Repatha (evolocumab), approved for the treatment of hypercholesteremia. Dr. Grayson also played a role in the successful development of Orladeyo (berotralstat), approved for the treatment of hereditary angioedema (HAE). She has built and led high-functioning, cross-functional teams and has successfully led development programs of small and large molecule therapeutics in hematology (anemia, non-Hodgkin lymphoma, multiple myeloma, myeloproliferative disorders, acute leukemia, and other B- and T-cell malignancies), oncology (gastric, colorectal, and pancreatic carcinomas), nephrology, cardiology, metabolism, inflammatory and autoimmune diseases (lupus nephritis, ANCA vasculitis, asthma, rheumatoid arthritis), infectious diseases, biodefense, neurology, and rare diseases, including paroxysmal nocturnal hemoglobinuria (PNH), C3 glomerulopathy (C3G), IgA nephropathy (IgAN), primary membranous nephritis (PMN), lupus nephritis, atypical hemolytic uremic syndrome (aHUS), and other indications. Dr. Grayson’s experience in medical affairs includes identifying and managing key opinion leaders and stakeholders, developing and managing advisory boards, developing clinical and scientific research studies to support pipeline and marketed products, medical and scientific communication, and translating key scientific and clinical findings to drive commercial strategies for approved and developmental-stage products in hematology, oncology, and nephrology. Dr. Grayson played a key leadership role in successfully raising over $120 million for several biotechnology companies. Her research has been published in prominent journals, such as Nature, and featured in the New York Times.
Listed skills include Biotechnology, Clinical Development, Oncology, Infectious Diseases, and 46 others.
Current workplace
Dena Grayson, Md, Phd's current company
Company context helps verify the profile and gives searchers a useful next step.
11 roles · 24 years
Dena Grayson, Md, Phd work experience
A career timeline built from the work history available for this profile.
Senior Vice President
CurrentExecutive leader overseeing Clinical Development, Clinical Sciences, and Clinical Pharmacology, leading the development of Keros’ pipeline products:-Elritercept (KER-050): Phase 3 trial myelodysplastic syndromes (MDS) and Phase 2 trial in myelofibrosis (MF)-Cibotercept (KER-012): Phase 2 trial in pulmonary arterial hypertension (PAH)-KER-065 for the.
May 2023 - Present
Clinical Development And Medical Affairs Physician-Scientist
Executive leader for small molecule complement inhibitors being developed for the treatment of PNH, C3G, IgAN, PMN, atypical hemolytic uremic syndrome (aHUS), and other complement-mediated diseases.
2020 - 2023
~3 yrs
Clinical Development And Medical Affairs Leader
Led clinical development and medical affairs for fimepinostat (dual inhibitor of histone deacetylase [HDAC] and phosphotidyl-inositol 3 kinase [PI3K]) under development for the treatment of non-Hodgkin lymphoma (NHL) and other hematologic malignancies.
2018 - 2020
~2 yrs
Medical Affairs Leader
Medical affairs for duvelisib, approved for the treatment of chronic lymphocytic leukemia (CLL) that was also under development in non-Hodgkin lymphoma and T-cell lymphoma
2017 - 2018
~1 yr
Chief Medical Officer
Valor Biotherapeutics
Executive leader of clinical development, regulatory, and medical affairs for IGN002, a novel immuno-biotherapeutic being developed for the treatment of relapsed or refractory NHL.
2014 - 2017
~3 yrs
Vice President, Translational Medicine
Executive leader of translational medicine activities for AC607, a mesenchymal stem cell therapy for acute kidney injury (AKI).
Jan 2011 - Sep 2014
Vice President, Translational Medicine
Executive leader of clinical and translational science for therapeutic programs in multiple infectious disease indications
Jan 2008 - Sep 2010
Director Of Medical Sciences, Associate Director Of Licensing
Served as a leader of early clinical development programs of large molecule biologics and traditional small molecule drugs in multiple disease areas, including asthma, anemia, hyperlipidemia, myelodysplastic syndromes, heart failure, and pain.Successful in-licensing transaction with Cytokinetics ($75m upfront, $50m option, plus other milestones).
Sep 2003 - Jan 2008
Fellow, Henry Crown Fellowship Program
The Henry Crown Fellowship Program seeks to develop the next generation of community-spirited leaders, providing them with the tools necessary to meet the challenges of business and civic leadership in the 21st century. The program is a unique mix of seminars designed to broaden the perspectives of the participants and hone their skills in values-centered.
2006 - 2008
~2 yrs
Engagement Manager
Medacorp
Strategic biotechnology and pharmaceutical consulting
2002 - 2003
~1 yr
3 education records
Dena Grayson, Md, Phd education
M.D., Ph.D., Medicine, Biochemistry
Washington University School Of Medicine In St. Louis
Residency, Internal Medicine Residency Program
University Of California, San Francisco - School Of Medicine
Bachelor Of Science (B.S.), Biochemistry And Molecular Biology
University Of Florida
FAQ
Frequently asked questions about Dena Grayson, Md, Phd
Quick answers generated from the profile data available on this page.
What company does Dena Grayson, Md, Phd work for?
Dena Grayson, Md, Phd works for Kyverna Therapeutics.
What is Dena Grayson, Md, Phd's role at Kyverna Therapeutics?
Dena Grayson, Md, Phd is listed as Senior Vice President, Clinical Development and Medical Affairs at Kyverna Therapeutics.
What is Dena Grayson, Md, Phd's email address?
AeroLeads has found 1 work email signal at @kerostx.com for Dena Grayson, Md, Phd at Kyverna Therapeutics.
Where is Dena Grayson, Md, Phd based?
Dena Grayson, Md, Phd is based in United States, United States, United States while working with Kyverna Therapeutics.
What companies has Dena Grayson, Md, Phd worked for?
Dena Grayson, Md, Phd has worked for Kyverna Therapeutics, Keros Therapeutics, Biocryst Pharmaceuticals, Inc., Curis, and Verastem Oncology.
How can I contact Dena Grayson, Md, Phd?
You can use AeroLeads to view verified contact signals for Dena Grayson, Md, Phd at Kyverna Therapeutics, including work email, phone, and LinkedIn data when available.
What schools did Dena Grayson, Md, Phd attend?
Dena Grayson, Md, Phd holds M.D., Ph.D., Medicine, Biochemistry from Washington University School Of Medicine In St. Louis.
What skills is Dena Grayson, Md, Phd known for?
Dena Grayson, Md, Phd is listed with skills including Biotechnology, Clinical Development, Oncology, Infectious Diseases, R&D, Clinical Research, Cancer, and Biochemistry.
Find 750M verified contacts
Search by job title, company, industry, location, and seniority. Export verified B2B contact data when you need it.
Start free trial